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ABSTRACT
Purpose: To compare the aqueous humor (AH) concentrations of moxifloxacin 
0.5% and gatifloxacin 0.3% solutions alone or when treatment was combined 
with steroids, and to correlate these concentrations with the minimum inhibitory 
concentrations (MIC) for the most common endophthalmitis-causing organisms. 
Methods: Patients undergoing phacoemulsification were enrolled to receive 
one drop of one of the following solutions: moxifloxacin (G1), moxifloxacin + 
dexamethasone (G2), gatifloxacin (G3), or gatifloxacin + c (G4), every 15 min, 1h 
before surgery. AH samples were collected before surgery and analyzed using 
HPLC-tandem mass spectrometry. 
Results: The mean antibiotic concentrations in the AH were: G1= 1280.8 ng/mL; 
G2= 1644.3 ng/mL; G3= 433.7 ng/mL; and G4= 308.1 ng/mL. The mean con-
centrations statistically differed between G1 and G2 (p=0.01), and G3 and G4 
(p=0.008). All samples achieved the MIC for Staphylococcus epidermidis; 100% 
of the samples from G1 and G2, and 97% from G3 and G4 reached the MIC for 
fluoroquinolone-sensitive Staphylococcus aureus; 100% of the samples from 
G1 and G2, 88% from G3, and 72% from G4 reached the MIC for enterococci 
(p<0.001); and 100% of samples from G1 and G2, 59% from G3, and 36% from 
G4 reached the MIC for Streptococcus pneumoniae (p<0.001). For fluoroquino-
lone-resistant S. aureus, 23% from G1, 44% from G2, and no samples from G3 
or G4 achieved the MIC (p<0.001). 
Conclusions: Moxifloxacin + dexamethasone demonstrated a higher concen-
tration in the AH than the moxifloxacin alone. Gatifloxacin + steroids de-
monstrated less penetration into the anterior chamber than gatifloxacin alone. 
Moxifloxacin was superior to gatifloxacin considering the MIC for enterococci, 
S. pneumoniae, and fluoroquinolone-resistant S. aureus.
Keywords: Aqueous humor; Ophthalmic solutions; Antibiotic prophylaxis; Fluo-
roquinolones; Steroids; Adrenal cortex hormones; Anti-bacterial agents; Com pa-
rative study
RESUMO
Objetivos: Comparar a concentração no humor aquoso entre as soluções de mo­
xi floxacina 0,5% e gatifloxacina 0,3% sozinhas ou combinadas com corticosteroides, 
e correlacionar a concentração com a concentração inibitória mínima (MIC) para os 
agentes microbianos mais comumente relacionados a endoftalmites.
Métodos: Pacientes que seriam submetidos a cirurgia de catarata foram selecio­
nados para receber 1 gota a cada 15 min, 1 hora antes do procedimento de uma 
das seguintes soluções: moxifloxacina (G1), moxifloxacina + dexametasona (G2), 
gatifloxacina (G3) ou gatifloxacina + prednisolona (G4). Amostras do humor aquoso 
foram coletadas antes do início da cirurgia. Espectrofotometria de massa por HPLC 
determinou a concentração do antibiótico nas amostras. 
Resultados: A concentração media de antibiótico nas amostras foram: G1= 1280,8 ng/mL; 
G2= 1644,3 ng/mL; G3= 433,7 ng/mL; G4= 308,1 ng/mL. Concentração média 
entre G1 e 2 (p=0,01), e G3 e 4 (p=0,008). Todas as amostras alcançaram MIC para 
S. epidermidis; 100% das amostras do G1 e 2, e 97% do G3 e 4 atingiram o MIC para S. 
aureus fluoroquinolona­sensível; 100% das amostras do G1 e 2, 88% do G3 e 72% do 
G4 atingiram o MIC para Enterococci (p<0,001); e 100% das amostras do G1 e 2, 59% 
do G3 e 36% do G4 atingiram o MIC para S. pneumoniae (p<0,001). Para o S. aureus 
resistente a fluoroquinolona, 23% do G1, 44% do G2, e nenhuma das amostras G3 
e 4 atingiram o MIC (p<0,001). 
Conclusão: Moxifloxacina + dexamethasona demonstrou maior concentração no 
humor aquoso comparado com a moxifloxacina sozinha. Gatifloxacina + esteróide 
demonstrou menor penetração na câmara anterior comparado a solução de ga ti­
floxacin sem corticóide. A moxifloxacina foi superior a gatifloxacina considerando o 
MIC para Enterococci, S. pneumoniae e S. aureus fluorquinolona resistente.
Descritores: Humor aquoso; Soluções oftálmicas; Antibioticoprofilaxia; Fluo ro qui­
nolonas; Esteroides; Corticosteroides; Antibacterianos; Estudo comparativo
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INTRODUCTION
Fourth-generation fluoroquinolones are the antibiotics of choice 
for many ophthalmologists as a result of their bactericidal properties 
and broad-spectrum coverage against Gram-positive and Gram-ne-
gative organisms. Quinolones are bactericides that prevent bacterial 
DNA replication by inhibiting bacterial DNA gyrase and topoiso-
merase. Ocular penetration requires the pH of ophthalmic solutions 
to be around 7, which favors unionized drugs and higher lipid solu-
bility of drugs(1).
The topical use of ophthalmic drops is the oldest and easiest me-
thod of administering medications for treating ocular diseases. When 
instilled on the ocular surface, most of the drug is rapidly washed 
out as a result of the usual volume of the drop and the eye’s drainage 
system, although viscosity enhancers can increase this length of 
time. The limited tissue penetration with this method means that the 
topical delivery is ideal for external, corneal, and anterior segment 
diseases, but not for retinal or vitreous diseases(2,3). Topical adminis-
tration is simple, and patients are generally able to self-administer 
eye drops, although compliance with daily regimens can be low(4,5).
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Human studies have shown that moxifloxacin 0.5% results in 
high concentrations in the anterior chamber(6-8). Treatment with 
a combination of steroids and antibiotic drops is as effective as 
con ventional treatment for controlling inflammation after phacoe-
mulsification and intraocular lens (IOL) implantation(9-12). These 
drug combinations help reduce costs and also improve patient 
compliance by decreasing the number of applications. 
The purpose of the present study was to compare aqueous hu-
mor (AH) concentrations of fluoroquinolones after topical instillation 
of moxifloxacin and gatifloxacin ophthalmic solutions alone or in 
combination with steroids, and to correlate these concentrations 
with the minimum inhibitory concentrations (MIC) for the most 
common endophthalmitis-causing organisms.
METHODS
This prospective clinical study was conducted from January 2012 
to February 2013 at the Federal University of São Paulo and Hospital 
de Olhos Paulista according to the tenets of the Declaration of 
Helsinki. Institutional review board/ethics committee approval was 
obtained, and each patient provided written informed consent 
before enrolment in the study. 
Patients scheduled for routine phacoemulsification and IOL 
implantation were enrolled in this study. Exclusion criteria were 
patients with ocular surface diseases and those using topical and 
systemic steroids and antibiotics. Prior to surgery for cataract, they 
received one of the following commercially available solutions: 
Group 1: mo xifloxacin 0.5% (Vigamox; Alcon, Fort Worth, TX, USA); 
Group 2: moxifloxacin 0.5% combined with dexamethasone (Viga-
dexa; Alcon); Group 3: gatifloxacin (Zymar; Allergan, Dublin, Ireland); 
and Group 4 gatifloxacin combined with prednisolone (Zypred; Aller-
gan). Table 1 shows the pharmacological features of the solutions.
Patients received one drop four times, 1 h before surgery (15-min 
intervals), instilled by a person designated for that. Approximately 
0.150 mL of AH was obtained immediately before paracentesis and 
transferred to a propylene recipient before storage at -20°C until 
analysis. 
Moxifloxacin and gatifloxacin concentrations in the AH samples 
were determined by high-performance liquid chromatography-tandem 
mass spectrometry (HPLC-MS/MS) using an API 3200 AB Sciex mass 
spectrometry detector coupled to a Symbiosis Pharma HPLC sys-
tem (Spark® Holland, Emmen, the Netherlands) and an ACE® C18 
(100 × 4.6 mm, 5 µm) column. The mobile phase was composed of 
methanol: 0.1% formic acid (v/v), 43:57 (v/v) in the isocratic mode. 
The monitored mass transitions (precursor ion → product ion) 
were m/z 402.1 → m/z 358.2 for moxifloxacin and m/z 376.1 → m/z 
289.2 for gatifloxacin, in the positive electrospray ionization mode. 
The method was developed using gatifloxacin as the internal stan-
dard (IS) for moxifloxacin and moxifloxacin as the IS for gatifloxacin. 
The validated range was 5-2,000 ng/mL for both analytes, and for 
samples exceeding the upper limit of quantification, a previously 
validated dilution process was performed. Linearity, accuracy, pre-
cision, and stability were determined in a validation procedure in 
accordance with ANVISA’s bioanalytical guidelines. 
The samples were prepared using 50 µL of AH spiked with the 
IS solution, and the samples were cleaned up using the protein 
precipitation method with 10% perchloric acid. Moxifloxacin and 
gatifloxacin were quantified in the samples using a duplicated se-
ven-point calibration curve that was constructed using 60 mg/dL 
of bovine serum albumin as a surrogate matrix and defined using 
the linear regression method with 1/x.x ponderation. For all sample 
analyses, we included 5% quality control (QC) samples at low, me-
dium, and high concentrations. Run acceptance was based on the 
performance of the calibration standards and QC samples.
We evaluated whether each sample achieved the MIC for pa-
thogens commonly related to endophthalmitis. The standard MICs 
considered were published by McCulley et al.(8).
Statistical analysis was performed with Stata 14 software (Stata-
Corp. 2015. Stata Statistical Software: Revision 23. College Station, TX: 
StataCorp LP). The Mann-Whitney test was used to compare means 
between groups, and Fisher’s test was used to compare the catego-
rical data (MIC).
RESULTS
A total of 139 samples were collected, and table 2 shows the 
patients’ demographics. The mean antibiotic concentrations in the 
Table 1. Pharmacological characteristics of the moxifloxacin solutions (Vigamox® and Vigadexa®) and gatifloxacin solutions (Zymar® and Zypred®)
Vigamox® Vigadexa® Zymar® Zypred®
Active principle(s) Moxifloxacin 
hydrochloride 0.5%
Moxifloxacin hydrochloride 0.5% Gatifloxacin 3 mg/mL Gatifloxacin 3 mg/mL
Dexamethasone 0.1% Prednisolone 10 mg/mL
pH 6.88 7.95 5.5-6.3 6.5-7.1
Solution Isotonic solution Isotonic non-tamponaded Isotonic non-tamponaded
Vehicle Boric acid Edetate disodium Benzalkonium chloride Benzalkonium chloride
Sodium chloride Boric acid Edetate disodium Sodium phosphated dibasic dihydrate
Sodium hydroxide and/or 
hydrochloric acid
Sodium chloride Sodium chloride Edetate disodium
Boric acid Sorbitol Sodium hydroxide and/or hydrochloric acid Hypromellose
Purified water Tyloxapol Purified water Sodium hydroxide and/or hydrochloric acid
Sodium hydroxide and/or hydrochloric acid Purified water
Purified water
Table 2. Patient demographics of the groups receiving fluoroquinolones
Variable
Group Comparison-P value
1 2 3 4 Group 1 vs. 2 Group 3 vs. 4
Number of eyes 35 34 34 36
Age (years), mean (SD) 68.5 (12.3) 71.3 ( 9.8) 65.6 (12.4) 67.6 (11.7) 0.23* 0.69*
Gender, male (%) 13.0 (37.0) 12.0 (35.0) 15.0 (44.0) 15.0 (42.0)
SD= standard deviation; *= Mann-Whitney test.
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AH were: Group 1= 1280.8 ng/mL; Group 2= 1644.3 ng/mL; Group 3= 
433.7 ng/mL; and Group 4= 308.1 ng/mL. The differences between 
the mean concentrations were statistically significant for groups 1 
and 2 (p=0.01), and groups 3 and 4 (p=0.008).
All samples from the four groups achieved the MIC for Staphylo­
coccus epidermidis; 100% of the samples from groups 1 and 2, and 
97% samples from groups 3 and 4 reached the MIC for fluoroquino-
lone-sensible Staphylococcus aureus, with no statistically significant 
difference (p=0.087) between the two antibiotics; 100% of the sam-
ples from groups 1 and 2, 88% sample from group 3, and 72% sample 
from group 4 reached the MIC for enterococci, with a statistically 
significant difference (p<0.001) between the two antibiotics; and 
100% of the samples from groups 1 and 2, 59% samples from group 
3, and 36% samples from group 4 reached the MIC for Streptococcus 
pneumoniae, with a statistically significant difference between the 
two antibiotics (p<0.001). Conversely, for fluoroquinolone-resistant 
(FQR) S. aureus, 23% from group 1, 44% from group 2, and no sample 
from groups 3 and 4 achieved the MIC, with a statistically significant 
difference found between the two antibiotics (p<0.001).
Table 3 shows the antibiotic concentrations in the AH in all groups 
and the percentage of samples that achieved the MICs. 
DISCUSSION
In the present study, we compared the ability of antibiotic drops 
alone and in combination with steroids to penetrate the anterior 
chamber before cataract surgery. The mean concentration in the 
group that received moxifloxacin 0.5% with dexamethasone was 
1644.3 ng/dL, which was higher than that of the group that received 
mo xifloxacin 0.5% alone (p=0.01). Between the gatifloxacin groups, 
the opposite results were observed: the mean concentration was 
higher in the group that received gatifloxacin without steroids 
(p=0.008).
The AH concentrations of moxifloxacin that we found are com-
patible with the MICs for the most common pathogens related to 
endophthalmitis. The samples from the gatifloxacin groups achieved 
the MICs for fluoroquinolone-sensible (FQS) S. epidermidis and FQS 
S. aureus. There was a statistically significant difference between 
gatifloxacin and moxifloxacin regarding the MICs for enterococci, S. 
pneumoniae, and FQR S. aureus. Fewer samples from the gatifloxacin 
group achieved the MICs for these pathogens. Interestingly, other 
studies have also reported the inferiority of gatifloxacin in achieving 
the MICs for enterococci, S. pneumoniae, and FQR S. aureus(8); there-
fore, surgeons should opt for moxifloxacin over gatifloxacin. 
A clinical study by Kim et al. showed AH concentrations of 
1800 ng/mL for moxifloxacin after instilling one drop of antibiotic 
every 10 min, with four doses, beginning 1h before cataract sur-
gery(7). Katz et al. reported an AH moxifloxacin concentration of 
1740 ng/mL with four-times-daily dosing the day before surgery 
plus one drop every 15 min for four doses before surgery(6). Fur-
ther, Solomon et al. showed an AH moxifloxacin concentration of 
1310 ng/mL after four-times-daily dosing for 3 days before surgery 
and one dose every 15 min for three doses 1h before surgery(13). 
These clinical studies demonstrated AH moxifloxacin concentrations 
similar to those found in our study. 
Kim et al. and McCulley et al. also reported gatifloxacin concen-
trations in AH after topical instillation of the drug without steroids. Kim 
et al. showed an AH concentration of 480 ng/mL for gatifloxacin after 
instilling one drop of antibiotic every 10 min for four doses beginning 
1h before cataract surgery(7,8). Additionally, McCulley et al. reported 
an AH gatifloxacin concentration of 940 ng/mL(8). The concentrations 
found in the present study are similar to those reported by Kim et al. 
and Solomon et al., which showed two-fold higher AH concentra-
tions for moxifloxacin over gatifloxacin: 1310 ng/mL and 630 ng/mL, 
with four-times-daily dosing for 3 days before surgery and one dose 
every 15 min for three doses 1 h before surgery, respectively(7,13). 
Although the topical administration of drugs is the preferred 
and most convenient route for treating ocular diseases, it is asso-
ciated with extremely limited bioavailability. The primaryt causes 
of drug loss are pre-corneal factors such as drainage; further, the 
tear turnover rate, and absorption by other tissues result in the 
loss of the drug to the systemic circulation. Some causes of the 
low ocular bioavailability may be the lipoidal nature of the corneal 
epithelium and the water-laden stroma, which work as rate-limiting 
barriers for hydrophilic and lipophilic molecules. Further, efflux 
transporters on the corneal epithelium may contribute to the low 
ocular bioavailability by actively effluxing molecules from the cornea 
back into the tear film. Multidrug resistance is primarily caused by 
the cellular extrusion of drugs by P-glycoprotein (P-gp), multidrug 
resistan ce-associated proteins (MRPs), and breast cancer resistance 
protein, which limit absorption across many biologic membranes 
and restrict entry into important pharmacologic sites(14). The ex-
pression and functional activity of P-gp and MRP2 in the rabbit and 
human corneal epithelia have been studied(15-17). In 2009, Hariharan 
et al. showed that steroids are effective at inhibiting both P-gp- and 
MRP2-mediated efflux across the rabbit cornea. Thus, steroids 
improve the ocular absorption of topically administered drugs by 
inhibiting efflux pumps on the cornea and elevating the cellular con-
centration of the drug in the cornea as well as the AH(18). This finding 
helps explain why the AH moxifloxacin concentration was higher in 
the group that received the combined solution.
Corneal permeability increases when the corneal integrity is com -
promised by the high concentrations of formulation excipients such 
as preservatives and chelating agents(19). Studies on the effect of 
for mulation additives on transcorneal permeability have revealed 
that compounds such as benzalkonium chloride (BAC), thiomersal 
(THM), chlorobutanol (CB), phenylmercuric nitrate, ethylenediamine 
Table 3. Mean moxifloxacin and gatifloxacin concentrations for each group; samples that achieved the MIC for the most common pathogens 
related to endophthalmitis in groups receiving moxifloxacin 0.5% or gatifloxacin 0.3% 
Variable
Group P value
1 2 3 4 Group 1 vs. 2 Group 3 vs. 4
Concentration (ng/mL) 1280.8 1644.3 433.7 308.1 <0.010* 0.008*
Median (Q1-Q3) (751.1-1743.1) (1043.1-2289.9) (289.4-649.8) (205.1-495.3)
MIC, yes (%) Groups 1-4 Group 3 vs. 4
FQS S. epidermidis 35 (100) 34 (100) 34 (100) 36 (100) <1.000† 1.000†<
FQS S. aureus 35 (100) 34 (100) 33 (097) 35 (097) <0.870† 0.740†<
S. pneumoniae 35 (100) 34 (100) 30 (088) 26 (072) <0.001† 0.080†<
Enterococci 35 (100) 34 (100) 20 (059) 13 (036) <0.001† 0.130†<
FQR S. aureus 08 (023) 15 (044) 00 (000) 00 (000) <0.001† 1.000†<
Q1= first quartile; Q3= third quartile; MIC= minimum inhibitory concentration; FQS= fluoroquinolone-sensible; FQR= fluoroquinolone-resistant; *= Mann-Whitney test.
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tetra-acetic acid (EDTA), methyl hydroxybenzoate (MHB), and propyl 
hydroxybenzoate increase the extent of transcorneal permeation at 
pH 7.4. BAC, THM, CB, and EDTA, have adverse effects on the corneal 
cell structure and integrity, and also increase drug permeability(20). 
Unfortunately, because of the small volume of the AH samples, 
we could not measure the concentration of steroids that penetrated 
the anterior chamber. This information could have explained why 
moxifloxacin penetrated the anterior chamber more than gatifloxacin 
when associated with steroids. Dexamethasone and prednisolone 
can have different effects on the corneal absorption of antibiotics. 
In conclusion, moxifloxacin in combination with dexamethasone 
demonstrated a higher concentration in the AH than moxifloxacin 
alone. Gatifloxacin in combination with steroids showed less pene-
tration in the anterior chamber than the steroid-free gatifloxacin 
solution. Moxifloxacin was superior to gatifloxacin considering the 
AH MICs for enterococci, S. pneumoniae and FQR S. aureus. The com-
mercial association of Vigamox with dexamethasone appears to be 
the best option for preoperative prophylaxis.
REFERENCES
 1. Pawar P, Katara R, Mishra S, Majumdar DK. Topical ocular delivery of fluoroquinolones. 
Expert Opin Drug Deliv. 2013;10(5):691-711. 
 2. Lau D, Leung L, Ferdinands M, Allen PJ, Fullinfaw RO, Davies GE, et al. Penetration of 
1% voriconazole eye drops into human vitreous humour: a prospective, open-label 
study. Clin Exp Ophthalmo. 2009;37(2):197-200. 
 3. Ottiger M, Thiel MA, Feige U, Lichtlen P, Urech DM. Efficient intraocular penetration 
of topical anti-TNF-α single-chain antibody (ESBA105) to anterior and posterior seg-
ment without penetration enhancer. Invest Ophthalmol Vis Sci. 2009;50(2):779-86. 
 4. Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persis-
tence among patients treated for glaucoma and ocular hypertension: a systematic 
review. Patient Prefer Adherence. 2011;5:441-63. 
 5. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose 
regimens and medication compliance. Clin Ther. 2001;23(8):1296-310. 
 6. Katz HR, Masket S, Lane SS, Sall K, Orr SC, Faulkner RD, et al. Absorption of topical mo-
xifloxacin ophthalmic solution into human aqueous humor. Cornea. 2005;24(8):955-8.
 7. Kim DH, Stark WJ, O’Brien TP. Ocular penetration of moxifloxacin 0.5% and gatifloxacin 
0.3% ophthalmic solutions into the aqueous humor following topical administration 
prior to routine cataract surgery. Curr Med Res Opin. 2005;21(1):93-4. 
 8. McCulley JP, Caudle D, Aronowicz JD, Shine WE. Fourth-generation fluoroquinolone 
penetration into the aqueous humor in humans. Ophthalmology. 2006;113(6):955-9. 
 9. Freitas LL, Soriano E, Muccioli C, Hofling-Lima AL, Belfort R Jr. Efficacy and tolerability 
of a combined moxifloxacin/dexamethasone formulation for topical prophylaxis and 
reduction of inflammation in phacoemulsification: a comparative, double masked 
clinical trial. Curr Med Res Opin. 2007;23(12):3123-30. 
 10. Mohan N, Gupta V, Tandon R, Gupta SK, Vajpayee RB. Topical ciprofloxacin-dexame-
thasone combination therapy after cataract surgery: randomized controlled clinical 
trial. J Cataract Refract Surg. 2001;27(12):1975-8. 
 11. Espiritu CR, Sy ME, Tayengco TL. Efficacy and tolerability of a combined moxifloxacin/
dexamethasone formulation for topical prophylaxis in phacoemulsification: an 
open-label single-arm clinical trial. J Ophthalmol. 2011;2011:769571. 
 12. Cunha PA, Shinzato FA, Tecchio GT, Webe SL, Brasil A, Avakian A. Efficacy and tolera-
bility of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis 
and control of inflammation in phacoemulsification: a 20-day-double-blind compa-
rison to its individual components. Clinics (Sao Paulo). 2013;68(6):834-9. 
 13. Solomon R, Donnenfeld ED, Perry HD, Snyder RW, Nedrud C, Stein J, et al. Penetration 
of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into 
the aqueous humor. Ophthalmology. 2005;112(3):466-9. 
 14. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cas-
sette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3-29. 
 15. Dey S, Patel J, Anand BS, Jain-Vakkalagadda B, Kaliki P, Pal D, et al. Molecular evidence 
and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and 
corneal epithelial cell lines. Invest Ophthalmol Vis Sci. 2003;44(7):2909-18. 
 16. Karla PK, Pal D, Mitra AK. Molecular evidence and functional expression of multidrug 
resistance associated protein (MRP) in rabbit corneal epithelial cells. Exp Eye Res. 
2007;84(1):53-60. 
 17. Karla PK, Pal D, Quinn T, Mitra AK. Molecular evidence and functional expression of a 
novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and 
its role in ocular drug efflux. Int J Pharm. 2007;336(1):12-21. 
 18. Hariharan S, Gunda S, Mishra GP, Pal D, Mitra AK. Enhanced corneal absorption of 
erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticos-
teroids. Pharm Res. 2009;26(5):1270-82. 
 19. Wang W, Sasaki H, Chien DS, Lee VH. Lipophilicity influence on conjunctival drug 
penetration in the pigmented rabbit: a comparison with corneal penetration. Curr Eye 
Res. 1991;10(6):571-9. 
 20. Chandran S, Roy A, Saha RN. Effect of pH and formulation variables on in vitro trans-
corneal permeability of flurbiprofen: a technical note. AAPS PharmSciTech. 2008;9(3): 
1031-7.
